Hinge Health stock pops 6% after first quarterly report since IPO

Hinge Health stock pops 6% after first quarterly report since IPO


Hinge Health co-founders, Gabriel Mecklenburg and Daniel Perez celebrate its initial public offering at the New York Stock Exchange on May 22, 2025.

NYSE

Shares of Hinge Health popped 6% in extended trading on Tuesday after the digital physical therapy company reported quarterly results for the first time since its debut on the New York Stock Exchange in May.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Loss: Loss per share of $13.10. That may not compare with the 9 cents per share earnings expected
  • Revenue: $139 million vs. $125 million expected

Revenue at Hinge increased 55% in the second quarter from $89.8 million during the same period last year, according to a release.

Hinge reported a net loss of $575.65 million, or $13.10 per share, compared to a loss of $12.93 million, a loss of 96 cents per share, during the same period a year earlier. The company said its GAAP loss from operations was $580.7 million, which included $591.0 million from stock-based compensation expenses.

“We’re still introducing ourselves to the world,” Hinge CEO Daniel Perez told CNBC in an interview on Tuesday. “The most important thing I’d hope for people to take away is the long-term potential of using software and connected hardware to automate care delivery itself.”

Hinge, founded in 2014, uses software to help patients treat acute musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely.

It finished the second quarter with 2,359 clients, up 39% from 1,785 clients during the same period last year.

Hinge said it expects to report revenue between $141 million and $143 million during its third quarter. LSEG analysts were expecting $129 million. For the full year, the company said it expects revenue of $548 million to $552 million, which also beat the $511 million expected by LSEG analysts.

The stock opened at $39.25 in May, rising 23% from its $32 IPO price. Shares of Hinge closed at $48.22 on Tuesday.

“We believe we’re fundamentally reshaping how care can be delivered more effectively and efficiently,” Perez said during the company’s quarterly call with investors.

Stock Chart IconStock chart icon

hide content

Hinge Health 3 month stock chart.

I'd consider buying Hinge Health at these levels, says Jim Cramer



Source

Inside politics of broken, unaffordable U.S. health care, Cityblock CEO Toyin Ajayi sees opportunity
Health

Inside politics of broken, unaffordable U.S. health care, Cityblock CEO Toyin Ajayi sees opportunity

For the first time in decades, people are having real conversations about health care, “from the ground up,” says Dr. Toyin Ajayi. That has her feeling optimistic. “We’re in a moment where health and health care — and what it means to be healthy — is the subject of a national discussion,” the co-founder and […]

Read More
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Health

Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq

Methodiq brand advertisement. Courtesy: Methodiq Il Makiage parent company Oddity is branching out into medical-grade skin care with its new brand Methodiq, as the online retailer looks to compete with Hims and help to address what it called a “broken medical care system.”  Methodiq, which has been in the works for four years and launched […]

Read More
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to 9 a month
Health

Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month

Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to […]

Read More